New recovery protocol aims to get stomach cancer patients home sooner
NCT ID NCT03997162
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests an enhanced recovery after surgery (ERAS) protocol in 52 people with stage 0 to IIIC gastric cancer who are having surgery. The goal is to see if this approach can reduce pain, nausea, and hospital stays while improving quality of life. Participants receive standard care plus questionnaires to track their recovery and well-being.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- enhanced recovery after surgery protocol (standard care plus quality-of-life assessments and questionnaires)
- What this could lead to
- If successful, this could establish a standard recovery plan that helps gastric cancer patients feel better faster after surgery and spend fewer days in the hospital.
- What could go wrong
- This is a small, single-center trial with only 52 participants, so results may not apply to all patients. The protocol is based on standard care, so major breakthroughs are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
52 people
The number who actually took part.
- Started
-
Oct 2018
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a biopsy proven diagnosis of gastric adenocarcinoma who are undergoing curative gastric surgery or prophylactic total gastrectomy for genetic risk
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients to be included are those with a biopsy proven diagnosis of gastric adenocarcinoma who are undergoing curative gastric surgery or prophylactic total gastrectomy for genetic risk. * Patients with clinical stage 0-IIIC will be included. * Any performance status and any life expectancy. * The effects of gastric surgery on the developing fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately. * All subjects must have the ability to understand and the willingness to sign a written informed consent. * Prior therapy will not be used as a limitation in this study. Exclusion Criteria: * Patients will be excluded if they are not candidates for surgery * Patients will be excluded from the study if they have had prior gastric surgery, with the exception of a gastrostomy tube. * Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clinical stage 0 gastric cancer ajcc V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding immunotherapy to standard cancer care be safe for indian patients?
- Can a targeted drug duo boost the power of surgery for stomach cancer?
- Can frailty predict recovery after gastric cancer surgery?
- Can a single surgery technique improve life after stomach cancer in two countries?
- Blood test may spot hidden stomach cancer recurrence risk
- Mapping Real-World care for stomach cancer in greece